Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial.

医学 吉西他滨 奥沙利铂 伦瓦提尼 内科学 肿瘤科 化疗 临床研究阶段 胃肠病学 外科 索拉非尼 癌症 肝细胞癌 结直肠癌
作者
Zhou Jian,Jia Fan,Guo–Ming Shi,Xiaoyong Huang,Dong Wu,Guo‐Huan Yang,Yuan Ji,Yi Chen,Fei Liang,Jia‐Cheng Lu,Ningling Ge,Hui‐Chuan Sun,Xiaowu Huang,Shuang‐Jian Qiu,Yifeng He,Xin‐Rong Yang,Yang Xu,Qiang Gao,Jian Sun
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:39 (15_suppl): 4094-4094 被引量:22
标识
DOI:10.1200/jco.2021.39.15_suppl.4094
摘要

4094 Background: The outcome of advanced intrahepatic cholangiocarcinoma (ICC) remains poor with current gemcitabine-based chemotherapy. This study is to evaluate the safety and efficacy of anti-PD1 agent toripalimab, lenvatinib in combination with oxaliplatin and gemcitabine (Gemox) chemotherapy. Methods: Locally advanced or metastatic ICC patients (pts) were given 240 mg toripalimab Q3W via intravenous (IV) infusion, 8 mg lenvatinib QD orally, and 1g/m² gemcitabine on Day 1 and Day 8, and 85 mg/m² oxaliplatin Q3W by IV for 6 cycles. The primary outcome was objective response rate (ORR), which was evaluated according to RECIST v1.1. Secondary outcomes included safety, progression-free survival (PFS) and overall survival (OS). Treatment would be terminated by confirmed disease progression, unacceptable toxicity, or voluntary withdrawal. Whole exome sequencing was performed on available tumor tissues and PD-L1 expression was determined by immunohistochemistry staining. Results: From May 2019 to Oct 2019, 30 pathologically-confirmed advanced ICC pts with a mean age of 56.5 (range, 25-73) years, including 11 women (37%), were enrolled at Zhongshan Hospital, Fudan University (one pt withdrawn). At the end of last follow-up (February 1, 2021), the ORR was 80% (24/30; 95% CI: 61.4%-92.3%), and disease control rate (DCR) was 93.3% (28/30; 95% CI:77.9%-99.2%). Median follow-up was 16.6 months. One pt achieved complete response (CR). Three pts with locally advanced disease were down-staged and then underwent resection. They remained disease-free survival at the end of last follow-up. 23 pts experienced disease progression and 12 pts (including one pt withdrawn) have died. The median PFS was 10.0 months and median duration of response (DOR) was 9.8 months. The median OS have not been reached. 12-months OS rate was 73.3% (95% CI: 57.5%-89.2%). No grade 5 adverse event (AE) was observed in present study. Grade 3 or 4 neutropenia and thrombocytopenia observed in 3 (10%) and 1 (3.3%) patient, respectively. Non-hematological toxic effects were jaundice (10 %), rash (6.7 %), proteinuria (6.7 %), increased AST level (3.3%), vomiting (3.3%), upper gastrointestinal hemorrhage (3.3%), sepsis (3.3%), gastrointestinal fistula (3.3%), adrenocortical insufficiency (3.3%), interstitial pneumonia (3.3%), and hyponatremia (3.3%). High ORR was significantly associated with positive PD-L1 expression ( p= 0.048) and DNA damage repair (DDR)-related mutations ( p= 0.022) in tumor samples. Conclusions: Gemox chemotherapy in combination with Anti-PD1 antibody Toripalimab and Lenvatinib provided remarkable efficacy with reasonable tolerability in advanced ICC patients. These findings warrant further validation in a large randomized clinical trial. Clinical trial information: NCT03951597.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
葉鳳怡完成签到 ,获得积分10
2秒前
2秒前
2秒前
1瞬间完成签到,获得积分10
2秒前
2秒前
卿总未梦完成签到,获得积分10
4秒前
5秒前
Mint发布了新的文献求助10
6秒前
xuerw完成签到 ,获得积分10
6秒前
9秒前
SCI发布了新的文献求助10
9秒前
找不完完成签到,获得积分20
10秒前
11秒前
13秒前
lll完成签到,获得积分10
13秒前
13秒前
辛勤念瑶发布了新的文献求助10
14秒前
yang发布了新的文献求助10
15秒前
15秒前
16秒前
xuxx完成签到,获得积分10
16秒前
共享精神应助单纯靖易采纳,获得10
17秒前
18秒前
18秒前
09发布了新的文献求助10
19秒前
小蘑菇应助满儿采纳,获得10
20秒前
20秒前
我爱螺蛳粉完成签到 ,获得积分10
20秒前
Singularity发布了新的文献求助10
21秒前
23秒前
23秒前
spy发布了新的文献求助10
23秒前
哈哈哈完成签到,获得积分20
23秒前
农学小王完成签到 ,获得积分10
24秒前
小冰子发布了新的文献求助10
24秒前
一给我里giao完成签到,获得积分10
25秒前
辛勤念瑶完成签到,获得积分10
25秒前
27秒前
27秒前
高分求助中
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
CLSI EP47 Evaluation of Reagent Carryover Effects on Test Results, 1st Edition 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
Retention of title in secured transactions law from a creditor's perspective: A comparative analysis of selected (non-)functional approaches 500
"Sixth plenary session of the Eighth Central Committee of the Communist Party of China" 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3055748
求助须知:如何正确求助?哪些是违规求助? 2712398
关于积分的说明 7431409
捐赠科研通 2357400
什么是DOI,文献DOI怎么找? 1248780
科研通“疑难数据库(出版商)”最低求助积分说明 606786
版权声明 596163